Arvind Ravi

Arvind Ravi is an Instructor in Medicine at Harvard Medical School, affiliated with the Broad Institute and actively contributing to the Getz Laboratory. His work bridges computational biology and clinical oncology with a focus on cancer immunotherapy.

His educational background includes:

• MD/PhD from Harvard-MIT Health Sciences and Technology (HST) Program (2014)
• Internal Medicine Residency at Brigham and Women’s Hospital
• Fellowship in Dana-Farber Cancer Institute/Massachusetts General Hospital Partners CancerCare Program

Dr. Ravi's research specializes in genomic and transcriptomic analysis of immunotherapy response in advanced cancers, particularly non-small cell lung cancer. He develops high-throughput platforms for profiling cancer resistance mechanisms and biomarker identification through the Stand Up To Cancer Dream Team initiative. His work integrates tumor genomics with immune microenvironment characterization to predict checkpoint inhibitor outcomes.

His publication record reveals a concentrated focus on translational cancer genomics, with recent work establishing molecular signatures for immunotherapy response across lung cancer and melanoma. Key contributions include joint tumor-immune profiling frameworks and computational tools for large-scale RNA-seq analysis.

Dr. Ravi maintains active roles in the Getz Laboratory at the Broad Institute and the Stand Up To Cancer-Mark Foundation cohort, collaborating across Dana-Farber Cancer Institute, Massachusetts General Hospital, and multiple Harvard-affiliated institutions to advance precision oncology.